Equities Analysts Issue Forecasts for NTLA FY2029 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities research analysts at Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for shares of Intellia Therapeutics in a research note issued to investors on Monday, January 6th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings of $93.13 per share for the year. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.12) per share.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The company had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. Intellia Therapeutics’s revenue for the quarter was down 24.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.38) earnings per share.

A number of other research analysts have also commented on NTLA. Stifel Nicolaus lowered their price objective on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a research note on Wednesday, September 11th. Barclays lowered their price target on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. The Goldman Sachs Group cut their price objective on Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Wedbush reaffirmed a “neutral” rating and set a $14.00 target price on shares of Intellia Therapeutics in a report on Monday, November 18th. Finally, Chardan Capital upped their price target on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a report on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $54.94.

Intellia Therapeutics Trading Down 2.6 %

NTLA stock opened at $12.47 on Wednesday. The firm’s 50-day moving average is $14.01 and its two-hundred day moving average is $19.28. The company has a market capitalization of $1.27 billion, a price-to-earnings ratio of -2.29 and a beta of 1.83. Intellia Therapeutics has a 52 week low of $11.34 and a 52 week high of $34.87.

Insider Transactions at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 28,735 shares of company stock valued at $349,909 over the last quarter. Company insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

A number of large investors have recently made changes to their positions in the business. State Street Corp grew its position in Intellia Therapeutics by 17.9% during the third quarter. State Street Corp now owns 5,143,534 shares of the company’s stock valued at $105,700,000 after purchasing an additional 780,754 shares in the last quarter. ARK Investment Management LLC boosted its stake in shares of Intellia Therapeutics by 5.7% during the 3rd quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock valued at $251,849,000 after buying an additional 659,651 shares during the period. Federated Hermes Inc. grew its holdings in shares of Intellia Therapeutics by 19.2% during the 2nd quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company’s stock valued at $51,494,000 after acquiring an additional 371,189 shares in the last quarter. Two Sigma Advisers LP increased its stake in shares of Intellia Therapeutics by 33.5% in the third quarter. Two Sigma Advisers LP now owns 1,027,617 shares of the company’s stock worth $21,118,000 after acquiring an additional 257,700 shares during the last quarter. Finally, Sphera Funds Management LTD. increased its stake in shares of Intellia Therapeutics by 108.8% in the third quarter. Sphera Funds Management LTD. now owns 291,080 shares of the company’s stock worth $5,982,000 after acquiring an additional 151,661 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.